Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction

Therapeutic Advances in Urology

Volumn 5, Issue 4, 2013, Pages 211-218

  Glina, Sidney ^a   Glina, Felipe Placco Araujo ^b  

^a Instituto H Ellis   (Brazil)

^b Faculdade de Medicina de Santos FMS   (Brazil)

Author keywords

benign prostatic hyperplasia; erectile dysfunction; lower urinary tract symptoms

Indexed keywords

ALFUZOSIN; DOXAZOSIN; MIRODENAFIL; SILDENAFIL; TADALAFIL; TAMSULOSIN; UDENAFIL; VARDENAFIL;

ARTERIOSCLEROSIS; DRUG MECHANISM; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SYSTEMATIC REVIEW;

EID: 84880881192     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287213488236     Document Type: Review

References (49)

1. Andersson K. (2001) Pharmacology of penile erection. Pharmacol Rev 53: 417–450.
2. Angulo J. Cuevas P. Fernández A. La Fuente J.M. Allona A. Moncada I. Sáenz de Tejada I. (2012) Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sexual Med 9: 2293–2306.
3. Bertolotto M. Trincia E. Zappetti R. Bernich R. Savoca G. Cova M.A. (2009) Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. Radiol Med 114: 1106–1114.
4. Bivalacqua T.J. Usta M.F. Champion H.C. Kadowitz P.J. Hellstrom W.J. (2003) Endothelial dysfunction in erectile dysfunction: Role of the endothelium in erectile physiology and disease. J Androl 24(6 Suppl.): S17–S37.
5. Bloch W. Klotz T. Loch C. Schmidt G. Engelmann U. Addicks K. (1997) Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 33: 1–8.
6. Braun M. Wassmer G. Klotz T. Reifenrath B. Mathers M. Engelmann U. (2000) Epidemiology of erectile dysfunction: results of the ‘‘Cologne Male Survey––. Int J Impotence Res 12: 305–311.
7. Chang S. Hypolite J.A. Zderic S.A. Wein A.J. Chacko S. Disanto M.E. (2005) Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am J Physiol 289: R1124–R1130.
8. Chute C.G. Panser L.A. Girman C.J. Oesterling J.E. Guess H.A. Jacobsen S.J. Lieber M.M. (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150: 85–89.
9. Demir O. Ozdemir I. Bozkurt O. Aslan G. Esen A.A. (2009) The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia. Asian J Androl 11: 716–722.
10. El-Sakka A. (2005) Lower urinary tract symptoms in patients with erectile dysfunction: is there a vascular association? Eur Urol 48: 319–325.
11. Feldman H.A. Goldstein I. Hatzichristou D.G. Krane R.J. McKinlay J.B. (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54–61.
12. Gacci M. Corona G. Salvi M. Vignozzi L. McVary K.T. Kaplan S.A. Roehrborn C.G. Serni S. Mirone V. (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61: 994–1003.
13. Glina S. Santana A.W. Azank F. Mello L.F. Moreira E.D. Jr. (2006) Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing men. Br J Urol Int 97: 763–765.
14. Glina S. Shindel A. Eardley I. Ghanem H. (2008) Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence by GS Brindley. J Sexual Med 5: 1791–1794.
15. Gur S. Kadowitz P.J. Sikka S.C. Bivalacqua T.J. Hellstrom W.J. (2012) Inhibition of sympathetic neuroeffector transmission in human corpus cavernosum. Br J Urol Int 110: 856–862.
16. Gur S. Sikka S.C. Chandra S. Koka P.S. Agrawal K.C. Kadowitz P.J. Hellstrom W.J. Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. Br J Urol Int 102: 1651–1657.
17. Jung J. Jae S. Kam S. (2009) Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: Impact of treatment of LUTS on sexual function. J Sexual Med 6: 2299–2304.
18. Jung J.H. Jae S.U. Kam S.C. Hyun J.S. (2009) Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function. J Sexual Med 6: 2299–2304.
19. Kedia G.T. Uckert S. Jonas U. Kuczyk M.A. Burchardt M. (2008) The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 26: 603–609.
20. Kobayashi K. Kato R. Hisasue S. Yamashita S. Tanaka T. Masumori N. Tsukamoto T. (2011) Animal model for the study of the relationship between lower urinary tract symptoms/bladder outlet obstruction and erectile dysfunction. Int J Urol 18: 710–715.
21. Laumann E. Paik A. Rosen R. (1999) Sexual dysfunction in the United States. Prevalence and predictors. J Am Med Assoc 281: 537–544.
22. Lee J.Y. Cho S.Y. Oh C.Y. Ha U.S. Lee S.H. Park S.Y. Moon H.S. Lee S.W. (2011) Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impotence Res 23: 249–256.
23. Lee Y.C. Wu W.J. Liu C.C. Wang C.J. Li W.M. Huang C.H. Yeh H.C. Ke H.L. Huang S.P. (2009) The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. J Sexual Med 6: 3158–3165.
24. Lin W.Y. Chang P.J. Lin Y.P. Wu S.B. Chen C.S. Levin R.M. Wei Y.H. (2012) Increased penile expression of transforming growth factor and elevated systemic oxidative stress in rabbits with chronic partial bladder outlet obstruction. Int J Androl 35: 79–85.
25. Lombardi G. Mondaini N. Giubilei G. Macchiarella A. Lecconi F. Del Popolo G. (2008) Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function. J Sexual Med 5: 2135–2140.
26. Martínez-Salamanca J.I. Carballido J. Eardley I. Giuliano F. Gratzke C. Rosen R. Salonia A. Stief C. (2011) Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol 60: 527–535.
27. McVary K.T. Razzaq A. Lee C. Venegas M.F. Rademaker A. McKenna K.E. (1994) Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 51: 99–107.
28. McVary K.T. Monnig W. Camps J.L. Jr. Young J.M. Tseng L.J. van den Ende G. (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071–1077.
29. Minagawa T. Aizawa N. Igawa Y. Wyndaele J.J. (2012) Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. Br J Urol Int 110(6 Pt B): E259–E266.
30. Morillo L.E. Díaz J. Estevez E. Costa A. Méndez H. Dávila H. Medero N. Rodriguez N. Chaves M. Vinueza R. Ortiz J.A. Glasser D.B. (2002) Prevalence of erectile dysfunction in Colombia, Ecuador, and Venezuela: a population-based study (DENSA). Int J Impotence Res 14(Suppl. 2): S10–S18.
31. Nasir A.R. Zehri A.A. Abbas F. Ather M.H. (2011) The correlation between international prostate symptoms score and sexual health inventory in men with lower urinary tract symptoms. Int Urol Nephrol 43: 625–629.
32. Nicolosi A. Moreira E.D. Jr. Shirai M. Bin Mohd Tambi M.I. Glasser D.B. (2003) Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 61: 201–206.
33. Oelke M. Giuliano F. Mirone V. Xu L. Cox D. Viktrup L. (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61: 917–925.
34. Oger S. Behr-Roussel D. Gorny D. Lecoz O. Lebret T. Denoux Y. Faix A. Leriche A. Wayman C. Alexandre L. Giuliano F. (2009) Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sexual Med 6: 836–847.
35. Oger S. Behr-Roussel D. Gorny D. Lebret T. Denoux Y. Alexandre L. Giuliano F. (2010) Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 57: 699–707.
36. Oudot A. Oger S. Behr-Roussel D. Caisey S. Bernabé J. Alexandre L. Giuliano F. (2012) A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat. Br J Urol Int 110: 1352–1358.
37. Öztürk M.I. Koca O. Sertkaya Z. Keles M.O. Kaya C. Karaman M.I. (2012) Acute effects of sildenafil on uroflowmetric parameters in erectile dysfunction patients with and without lower urinary tract symptoms. J Androl 33: 1165–1168.
38. Padma-Nathan H. Goldstein I. Klimberg I. Coogan C. Auerbach S. Lammers P; Vasomax Study Group. (2002) Long-term safety and efficacy of oral phentolamine mesylate (Vasomax) in men with mild to moderate erectile dysfunction. Int J Impotence Res 14: 266–270.
39. Ponholzer A. Temml C. Obermayr R. Madersbacher S. (2004) Association between lower urinary tract symptoms and erectile dysfunction. Urology 64: 772–776.
40. Porst H. Kim E.D. Casabé A.R. Mirone V. Secrest R.J. Xu L. Sundin D.P. Viktrup L; LVHJ study team. (2011) Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 60: 1105–1113.
41. Roehrborn C.G. Kaminetsky J.C. Auerbach S.M. Montelongo R.M. Elion-Mboussa A. Viktrup L. (2010) Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. British Journal of Urology International 105(4):502–507.
42. Seftel AD. de la Rosette J. Birt J. Porter V. Zarotsky V. Viktrup L. (2013) Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract 67: 32–45.
43. Shiri R. Häkkinen J.T. Hakama M. Huhtala H. Auvinen A. Tammela T.L. Koskimäki J. (2005) Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 174: 205–209.
44. Stief C.G. Porst H. Neuser D. Beneke M. Ulbrich E. (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236–1244.
45. Tamimi NA. Mincik I. Haughie S. Lamb J. Crossland A. Ellis P. (2005) A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. Br J Urol Int 106: 674–680.
46. Tarcan T. Azadzoi K.M. Siroky M.B. Goldstein I. Krane R.J. (1998) Age related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 82(Suppl. 1): 26–33.
47. Tinel H. Stelte-Ludwig B. Hütter J. Sandner P. (2006) Pre-clinical evidence for the use of hosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. Br J Urol Int 98: 1259–1263.
48. van Moorselaar R.J. Hartung R. Emberton M. Harving N. Matzkin H. Elhilali M. Alcaraz A. Vallancien G; ALF-ONE Study Group. (2005) Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. Br J Urol Int 95: 603–608.
49. Zhao C. Kim S.H. Lee S.W. Jeon J.H. Kang K.K. Choi S.B. Park J.K. (2011) Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Br J Urol Int 107: 1943–1947.